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RRhinotillexis: A Possible
Heuristic to Reduce Inappropriate
Noninvasive Cardiac Imaging?
Hachamovitch et al. (1) presented findings from the prospectively
acquired SPARC (Study of Myocardial Perfusion and Coronary
Anatomy Imaging Roles in Coronary Artery Disease [CAD])
registry. Enrolled patients had intermediate to high likelihood of
CAD and were referred for “clinically indicated” noninvasive
cardiac imaging tests. The authors reported data on medication
changes as well as referrals for both cardiac catheterization and
revascularization at 90 days, based on results of these imaging tests.
One of the main findings was a concerning lack of medical therapy
optimization and cardiac catheterization referrals in those found to
have moderately to severely abnormal findings on initial imaging
(1). This is particularly concerning because 80% of the SPARC
registry patients had “anginal symptoms” at enrollment (1). One
presumes that the majority of these had stable angina; however, it
would be helpful if the authors could report what proportion had
unstable angina (recognizing that chest pain at rest was one study
exclusion criterion [2]).
The authors reported that 24% of patients with moderately to
severely abnormal findings were not receiving aspirin, 44% were
not receiving beta-blockade, and 23% were not receiving lipid-
lowering agents at 90 days. These suboptimal results were accen-
tuated by the use of patient self-report for medication changes
(frequently overestimated [3]) and the relatively short duration of
follow-up. A number of studies have demonstrated a decline in
ongoing medication compliance months after initial imaging
results induced medication changes (4). We previously published
similar results from a large matched-cohort study evaluating the
impact of coronary computed tomography angiography (CCTA)
findings on secondary test referrals and medication use in a
lower-risk cohort (3). We found that our 90-day adjusted odds
ratios for aspirin use (6.8) and statin use (4.6) in those with
abnormal CCTA (compared with controls) were much reduced at
18 months (4.2 for aspirin and 3.3 for statins). The original
SPARC protocol also included assessment of medication use at 1
and 2 years’ follow-up (2). We wonder whether the authors can
report their medication use findings over longer follow-up.
Similarly, half of those with moderate to severe abnormalities
were not referred for cardiac catheterization. The authors posited
that the low number of catheterization referrals may have been due
to equipoise. Certainly, the widely disseminated results of the
COURAGE (Clinical Outcomes Utilizing Revascularization and
Aggressive Drug Evaluation) trial support this theory (5). That
aid, the SPARC study definition of a moderate to severe abnor-
ality on CCTA was “50% left main stenosis, 70% stenosis in
he proximal left anterior descending artery, or 3-vessel CAD with
70% stenosis.” With such high-grade CAD, it is disconcertingthat 40% of these symptomatic CCTA patients did not undergo
catheterization.
Thus, many patients are presumably being sent for wasteful
imaging tests because even markedly abnormal results do not
influence the referring physicians’ management. This brings to
mind a common medical heuristic from our hospital regarding
public displays of rhinotillexis, “you better have a plan if you find
something in there.” Physicians would do well to remember this
when ordering such cardiac imaging tests.
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CTCA Versus MPI 
Anatomical Versus Functional
Hachamovitch et al. (1) reported increased referral rates for
coronary angiography in patients with an intermediate to high
probability of coronary artery disease following coronary computed
tomography angiography (CCTA) as compared with myocardial
perfusion imaging (MPI). Several hypotheses for this discrepancy
were offered. Although these may well be correct, the fact remains
